期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

动脉粥样硬化和淀粉样变性疾病发病机制研究:血清淀粉样蛋白P与血浆脂蛋白的相互作用 被引量：2

Study on the pathogenesis of atherosclerosis and amyloid degeneration:the interaction between serum amylord P component and plasma lipoprotein
下载PDF
导出
摘要 目的:研究人血清中淀粉样蛋白P(serumamyloidP,SAP)与血浆脂蛋白中高密度脂蛋白(highdensitylipoprotein,HDL)、极低密度脂蛋白(verylowdensitylipoprotein,VLDL)和低密度脂蛋白(lowdensitylipoprotein,LDL)相互作用机制,为了解动脉粥样硬化和淀粉样变性疾病的发病机制提供理论依据。方法:①Sepharose4B(Pharmacia)亲和层析法提取人血清SAP,DEAE-Sepharose层析纯化。SDS-聚丙烯酰胺凝胶电泳与标准SAP(Sigma)检测。②采用免疫探针生物素化试剂盒(Sigma)以1:10比例接合于生物素氨基己酸-N-羟基-硫琥珀酰亚胺酯。得到生物素-SAP。③VLDL,LDL,HDL用超速离心法分离。④以四甲基联苯胺(TMBZ)底物试剂盒用固相平板测定法检测SAP与脂蛋白相互结合。结果:①生理条件的Ca2+水平下,生物素-SAP以剂量依赖方式选择性地与HDL,VLDL结合。当SAP水平分别达到1.5nmol/L和2nmol/L时,SAP与HDL,VLDL的结合达到半饱和,当SAP水平达到4nmol/L和16nmol/L时,SAP与HDL,VLDL结合达到饱和。②SAP与HDL和VLDL的结合具有Ca2+依赖性。③EDTA可影响SAP和HDL,VLDL结合。④无论有无Ca2+和EDTA存在,未发现SAP和LDL间的结合。结论:SAP与HDL和VLDL结合而不与LDL结合。 AIM:To study the mechanism of interaction between serum amyloid P(SAP) component and high density lipoprotein(HDL),very low density lipoprotein(VLDL) and low density lipoprotein(LDL),so as to provide theoretical evidence for the pathogenesis of atherosclerosis and amyloid degeneration. METHODS:①SAP was extracted from normal human serum by Sepharose 4B(Pharmacia) affinity adsorption and purified by chromatography on DEAE Sepharose.It was detected by using SDS polyacrylamidedel electrophoresis(PAGE) and standard SAP(Sigma)②urified SAP was conjugated to biotinamidocaprobe N hydroxy sulfosuccinimide ester by using an ImmunoProbe Biotinylation Kit(Sigma) at the ratio of 1 to 10,and biotin SAP was obtained.③VLDL,LDL and HDL were isolated from EDTA containing plasma by sequential ultracentrifugation in solution of potassium bromide.④The interaction between lipoprotein and SAP was analyzed by using a solid phase plate assay in a tetramethyl benzidine(TMBZ) kit. RESULTS:①Biotinylated SAP bound to immobilized HDL and VLDL in a calcium dependent,saturable manner.The SAP HDL and SAP VLDL bindings reached half saturation at 1.5 nmol/L and 2 nmal/L of SAP,and saturation at 4 nmol/L and 16 nmol/L of SAP,respectively.②SAP was bound with HDL and VLDL in a Ca2?dependent manner.③The bindings of SAP with HDL and VLDL could be affected by EDTA.④No binding between SAP and LDL was found in the presence or absence of calcium and EDTA.CONCLUSION:SAP binds with HDL and VLDL,but not with LDL.
作者 张凤珍 孙凌云 翟静 蒋汉明 史仁玖 张媛英 顾鸿雁
机构地区 泰山医学院生物化学教研室
出处 《中国临床康复》 CSCD 2004年第21期4216-4218,共3页 Chinese Journal of Clinical Rehabilitation
关键词 动脉粥样硬化 淀粉样变性疾病 发病机制 血清淀粉样蛋白P 血浆脂蛋白 相互作用
分类号 R543.5 [医药卫生—心血管疾病]
  • 相关文献

参考文献20

  • 1Emsley J,White HE,O' Hara BP,et al.Structure of pentameric human serum amloid P component.Nature 1994;367:338-45
  • 2Kiernan UA,Nedelkov D,Tubbs KA,et al.Proteomic characterization of novel serum amyloid P component variants from human plasma and urine.Proteomics 2004;4(6):1825-9
  • 3de Beer FC,Baltz ML,Holford S,et al.Fibronectin and C4-binding protein are selectively bound by aggregated amyloid P component.J Exp Med 1981;154:1134-9
  • 4Schwalbe RA,Dahlback B,Nelsestuen GL.Independent association of serum amyloid P componet,protein S,and component C4b with complement C4b-binding protein and subsequent association of the complex with membranes.J Biol Chem 1990;265:21749-57
  • 5Hamazake H.Ca2+-mediated association of human serum amyloid P component with heparan sulfate and dermatan sulfate.J Biol Chem 1987;262:1456- 60
  • 6Butler PJ,Tennent GA,Pepys MB.Pentraxin-chromatin interactions:serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin.J Exp Med 1990;172:13-8
  • 7Ying SH,Gewuiz AT,Jiang H,et al.Human serum amyloid P component oligomers bind and activate the classical component pathway via residues 14-26 and 76-92of the chain collagen-like region of Clq.J Immunol 1993;150:169-76
  • 8Brown MR,Anderson BE.Receptor-ligand interactions between serum amyloid P component and model soluble immune complexes.J Immunol 1993;151:2087-95
  • 9Christner RB,Mortensen RF.Specificity of the binding interaction between human serum amyloid P-component and immobilized human C-reactive protein.J Biol Chem 1994;269:9760-6
  • 10Hamazake H.Ca2 +-dependent Binding of Human Serum Amyloid P Component to Alzheimer' s-Amyloid Peptide.J Biol Chem 1995;270:10392-4

二级参考文献36

  • 1[1]Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Bene dek GB, Teplow DB. Amyloid beta-protein(Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A 2003; 100 (1): 330 -5
  • 2[2]Antzutkin ON, Leapman RD, Balbach JJ, Tycko R. Supramoiecular structural constraints on Alzheimer' s beta-amyloid fibrils from electron microscopy and solid-state nuclear magnetic resonance. Biochemistry 2002; 41 (51): 15436- 50
  • 3[3]Kobayashi T, Ota S, Tanaka K, et al. A novel L266V mutation of the tau gene causes frontotemporal dementia with a unique tau pathology. Ann Neurol 2003; 53(1 ):133 - 7
  • 4[4]Cook DG, Leverenz JB, McMillan PJ, et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer' s disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 2003; 162 (1): 313 - 9
  • 5[5]Davidsson P, Sjogren M, Andreasen N, et al. Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome snalysis of CSF proteins. Brain Res Mol Brain Res 2002; 109(1 -2): 128 -33
  • 6[6]Matsuoka Y, Saito M, LaFrancois J. Novel therapeutic approsch for the treatment of Alzheimer' s disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci2003; 23 (1): 29 - 33
  • 7[7]Weiner HL, Selkoe DJ. Inflammation and therapeutic vaccination in CNS diseases. Nature 2002; 420(6917): 879 - 84
  • 8[8]Kotwal GJ, Lahiri DK, Hicks R. Potential intervention by vaccinia virus complement control protein of the signals contributing to the progression of central nervous system injury to Alzheimer' s disease. Ann N Y Acad Sci 2002; 973:317 - 22
  • 9Castelli WP, Anderson K, Wilson PW, Levy D, Lipids and risk of coronary heart disease: the Framingham Study. Ann Epidemiol 1992; 2 ( 1 - 2) : 23 - 8.
  • 10Wierzbicki AS, Milchailidis DP, Beyond LDL-C-the importance of raising HDL-C.Curr Med Res Opin 2002:18(1):36-44.

共引文献54

同被引文献12

  • 1董孟杰,林祥通,赵军.β-淀粉样蛋白的特异性显像剂及研究进展[J].中华核医学杂志,2005,25(2):125-127. 被引量：1
  • 2Chen YW, Lee MJ,Smith EE.Cerebral amyloid angiopathy in East and West[J].Int J Stroke,2010,5(5):403-411.
  • 3Shi J,Yang SH,Stubley L,et.al.Hypoperfusion induces over expression of beta-amyloid precursor protein mRNA in a focal is Chemic Rodent model [J].Brain Res,2000,853(1): 1-4.
  • 4Bassiouny HS, Sakaguchi Y, Mikucki SA, et al.Juxtalumenal location of plaque necrosis and neoformation in symptomatic carotid stenosis.J Vasc Surg 1997;26(4):585-94
  • 5Jander S, Sitzer M, Schumann R, et al. Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization.Stroke 1998;29(8):1625-30
  • 6Stary HC.Natural history and histological classification of atherosclerotic lesions: an update.A rterioscler Thromb Vasc Biol 2000;20(5):1177-8
  • 7Ross R.Atherosclerosis-an inflammatory disease.N Engl J Med 1999;340(2):115-26
  • 8Pentikainen MO, Oorni K, Ala-Korpela M, et al. Modified LDL - trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med 2000;247(3):359-70
  • 9Jander S, Sitzer M, Wendt A, et al.Expression of tissue factor in high-grade carotid artery stenosis: association with plaque destabilization. Stroke 2001;32(4):850-4
  • 10殷小平,张曼青.影响脑出血微创颅内血肿清除术死亡和再出血的因素分析[J].内科急危重症杂志,2008,14(2):84-86. 被引量：13

引证文献2

二级引证文献6

中国临床康复
2004年 第21期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部